Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

By E. Cohen, L. Rosen, E. Vokes, M. Kies, A. Forastiere, F. Worden, M. Kane, E. Sherman, S. Kim, P. Bycott and 4 more. Journal of Clinical Oncology, 2008

656 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e6041be47be40538a69bc1ac8147b6a38b617d97

Citations in the corpus

• Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association (2009, neutral): “Currently, several kinase inhibitors are under evaluation in clinical trials and preliminary evidence indicates that they may have important clinical benefits (363).”
• Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, neutral): “Axitinib Cohen EE, 2008 [102] 45 30 18 Axitinib Locati LD, 2014 [103] 52 35 16 Cabozantinib Cabanillas ME, 2017 [104] 25 40 12.”
• American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer (2012, neutral): “Likewise, in a trial of all thyroid cancer histotypes, the tyrosine kinase inhibitor axitinib also yielded no responses in two treated ATC patients (196).”
• Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2015, neutral): “In recent years several tyrosine kinase inhibitors (TKIs) [axitinib, cabozantinib, gefitinib, imatinib, motesanib, sorafenib, sunitinib, and vandetanib] have been evaluated in phase I, II, and III clinical trials of patients with advanced MTC (340-350).”